Surgical Treatment of Distal Cholangiocarcinoma.
Leva GorjiEliza W BealPublished in: Current oncology (Toronto, Ont.) (2022)
Distal cholangiocarcinoma (dCCA) is a rare malignancy arising from the epithelial cells of the distal biliary tract and has a poor prognosis. dCCA is often clinically silent and patients commonly present with locally advanced and/or distant disease. For patients identified with early stage, resectable disease, surgical resection with negative margins remains the only curative treatment strategy available. However, despite appropriate treatment and diligent surveillance, risk of recurrence remains high with nearly 50% of patients experiencing recurrence at 5 years subsequent to surgical resection; therefore, it is prudent to continue to optimize neoadjuvant and adjuvant therapies in order to reduce the risk of recurrence and improve overall survival. In this review, we discuss the clinical presentation, workup and surgical treatment of dCCA.
Keyphrases
- study protocol
- end stage renal disease
- early stage
- poor prognosis
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- rectal cancer
- squamous cell carcinoma
- lymph node
- public health
- long non coding rna
- minimally invasive
- neoadjuvant chemotherapy
- patient reported outcomes
- combination therapy
- patient reported
- phase ii study